Menu
GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
    • Status of Assessments
    • Timeline of Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Contact Us
    • Call for Nomination
    • Topic Nomination
  • AUXILIARY MENU
  • GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
    • Status of Assessments
    • Timeline of Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Contact Us
    • Call for Nomination
    • Topic Nomination

Preliminary Recommendation

preliminary recommendation for the non-inclusion of eribulin in the treatment of soft tissue sarcoma in the PNF

preliminary recommendation for the inclusion of Potassium Citrate 1620 mg (15 mEq) tablet in the PNF.

preliminary recommendation for the inclusion of rituximab 1400 mg/ 11.7 mL solution for subcutaneous (SC) injection for the treatment of non-Hodgkin’s lymphoma

preliminary recommendation for the inclusion of vasopressin 20 IU/mL (IM/IV)

preliminary recommendation for the non-inclusion of pertuzumab for human epidermal growth factor receptor 2 (HER2)-positive breast cancer

preliminary recommendation for the inclusion of sambong 250mg tablets as anti-urolithiasis

Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-infection

PRELIMINARY RECOMMENDATION ON Dolutegravir (DTG)

Preliminary recommendation on Tenofovir/Lamivudine/Dolutegravir (TLD)

656188
Users Today : 686
This Month : 20984
Total Users : 656188
Your IP Address : 44.192.47.87
Philippine Standard Time:
✕

Philippine Society of Microbiology and Infectious Diseases (PSMID) releases Philippine COVID-19 Living Recommendations

View the document on their website: https://www.psmid.org/philippine-covid-19-living-recommendations/